Figures & data
Table 1 Chemical composition of rHDL/AD-32 particles
Figure 1 Loading efficiency of AD-32 into rHDL nanoparticles via the cholate dialysis process (see methods for details).
Abbreviations: AD-32, valrubicin; rHDL, reconstituted high-density lipoprotein.
Figure 2 Estimation of the diameter of the AD-32 containing rHDL nanoparticles by (A) dynamic light scattering, (B) atomic force microscopy, and (C) transmission electron microscopy.
Abbreviations: AD-32, valrubicin; rHDL, reconstituted high-density lipoprotein.
Figure 3 Distribution of the AD-32 containing rHDL nanoparticles subsequent to preparative ultracentrifugation (see text for experimental details).
Abbreviations: AD-32, valrubicin; rHDL, reconstituted high-density lipoprotein.
Table 2 Cytotoxicity of AD-32, delivered by rHDL nanocarriers versus the free drug against malignant and normal cells
Figure 4 Comparative drug uptake studies from rHDL/AD-32 nanoparticles with malignant and non-malignant ovarian and prostate cell lines.
Abbreviations: AD-32, valrubicin; rHDL, reconstituted high-density lipoprotein; PZ-HPV, nonmalignant prostate epithelial cell line; PC-3, prostate cancer cell line; HiO 180, nonmalignant ovarian epithelial cell line; SKOV-3, ovarian cancer cell line; HDL, high-density lipoprotein.
Table 3 The stability of AD-32/rHDL particles at different storage conditions
Figure 5 Release of AD-32 during dialysis when encapsulated in rHDL nanoparticles vs release of the free drug (see under Methods for experimental details).
Abbreviations: AD-32, valrubicin; rHDL, reconstituted high-density lipoprotein.
